Viewing Study NCT01702792


Ignite Creation Date: 2025-12-24 @ 3:14 PM
Ignite Modification Date: 2026-01-01 @ 10:58 AM
Study NCT ID: NCT01702792
Status: TERMINATED
Last Update Posted: 2018-04-04
First Post: 2012-10-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Derivation of Tumor Specific Hybridomas
Sponsor: Dartmouth-Hitchcock Medical Center
Organization:

Study Overview

Official Title: Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas
Status: TERMINATED
Status Verified Date: 2018-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Investigator is leaving Dartmouth
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a non-randomized, open-label study in patients with newly diagnosed glioblastoma to determine the ability to generate human hybridomas from lymph nodes draining an autologous tumor vaccine injection and demonstrate that the hybridomas secrete glioblastoma-specific antibodies.
Detailed Description: The intradermal vaccine will be injected 20cm in the anterior thigh. Vaccination will be done twice and separated by one week. The first vaccination will be performed approximately 2 weeks after surgery.

Approximately one week after the second vaccination one or two vaccine-draining lymph node(s) will be removed. The lymph node(s) will be identified using SN technology. One or two lymph node(s) will be removed.

Lymph nodes will be processed for recovery of B cells and formation of hybridomas.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: